TrialEvaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Trial details
- Registry ID
- NCT05509023
- Phase
- Phase 2
QTTB
Q32 Bio Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)NCT05509023 | QTTB | Phase 2 | Active not recruiting | 2024-12Estimated |
| A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)NCT06018428 | QTTB | Phase 2 | Active not recruiting | 2026-06Estimated |
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Trial details
- Registry ID
- NCT06018428
- Phase
- Phase 2
Latest recorded trial changes
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428 · Q32 Bio Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting